Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
admin 29th June 2018 Uncategorised 0Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
More: Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
Source: News